Identifying Prokineticin2 as a Novel Immunomodulatory Factor… : Critical Care Medicine

Ad Blocker Detected

Our website is made possible by displaying online advertisements to our visitors. Please consider supporting us by disabling your ad blocker.

Sepsis is designated as a highly lethal condition within the worldwide human population (1,2) and with a current infection rate estimated to be between 47 and 50 million people, culminates in the demise of 11 million individuals annually (3). Clinical biochemical research has inevitably involved challenging and extensive studies of sepsis pathogenesis and survival (4–7), yet reasons for high morbidity rates remain poorly understood. Clinical diagnosis of the disease and treatments thereof to improve patient survival have provided evidence-based practices, although many of these have been deemed ineffective (8,9) as, for example, Drotrecogin alfa (Xigris, activated protein C) was withdrawn after a decade of application (10). In view of a recent World Health Organization resolution (11), novel treatment regimens for sepsis are now being rigorously pursued.

Recent applications of molecular diagnostics have identified several contenders as biomarkers of sepsis (12); however, many fall short of the stringent criteria for translation into clinical use. For instance, procalcitonin, one enthusiastic biomarker in diagnoses of general sepsis, was transpired to be somewhat subjective in precision for diagnosis of early-onset neonatal sepsis for its naturally higher physiologic abundance and inequivalence in specificity (13,14). Furthermore, time-consuming blood culture, once considered to be a mainstay diagnostic criterion, has, in fact, been overshadowed owing to a high frequency of false-negative results.

High mortality rates in patients afflicted with sepsis that derives multiple organ failure, are considered to involve, among others, inflammatory disorders (15,16), immune cell paralysis (17–20), coagulopathy (21–23), and neuromuscular damage (24,25). These ultimately pertain to immune dysfunction (26,27). Our previous work revealed that representative macrophages, alongside a variety of bioactive cytokines, are central to the occurrence and development of sepsis, although the molecular mechanism for this is not well understood (28–32).

In this present study, we noted a surprising change in abundance of prokineticin2 in septic patients. This protein, originally identified as a member of the prokineticin family in Bauhinia variegata (33), was deemed to be a gastrointestinal secretory polypeptide involved in the regulation of peristalsis (34). Subsequently, prokineticin2 was also found to be widely expressed in a diverse array of tissues ranging from the CNS (35) and nonsteroidogenic cells of the testes (36) to immune cells (37,38). Signal transduction by prokineticin2 is mediated via two structurally homologous receptors PKRs (PKR1 and PKR2) (39). Prokineticin2 is associated with a variety of biological functions including neurodevelopment (35,40), angiogenesis (38,41), circadian rhythms (42), reproduction (43,44), and inflammatory discomfort (45). Alongside these, prokineticin2 promotes chemotaxis and alternative A2 reactivity of astrocytes (46).

Despite the overwhelming evidence in support for the role of prokineticin2 in multiple diseases, a direct correlation between the presence of this protein and the occurrence/development of sepsis, tied to a concomitant regulation of innate immunity and inflammation during sepsis, remains unclear. Here, we observed a significant correlation between the prokineticin2 hyposecretion and sepsis progression compared with a healthy control group. In an animal model, recombinant prokineticin2 (rPK2) administration significantly improved the survival rate of septic mice and somewhat alleviated sepsis-induced multiple organ damage associated with macrophage function. We thereby present a previously unrecognized aspect for the regulation of sepsis pathogenesis using prokineticin2-induced immunotherapy of the disease.


Detailed methods are available in the Online Supplement (

Study Population

Adult patients and pediatric patients who met the clinical criteria for sepsis-3 along with the consensus and criteria recommended by the Society of Critical Care Medicine and the European Society of Intensive Care Medicine (1) were enrolled at admission to the ICU of the First Affiliated Hospital of Chongqing Medical University and the Children’s Hospital of Chongqing Medical University, respectively. Patients with malignancy, organ transplantation, immunodeficiency disease, autoimmune diseases, pregnancy, and the use of immunosuppressive medication in the past 2 months were excluded from the study. Nineteen adult and 10 pediatric nonseptic patients (patients with severe pneumonia who meets the diagnostic criteria for pneumonia [47,48] but not for sepsis [1], Sequential Organ Failure Assessment score < 2) were recruited as patient controls. Specimens were collected after the patient was admitted to the ICU with sepsis or septic shock and before medical intervention. The clinical data, including WBCs, C-reaction protein and procalcitonin, microbial culture results, the length of ICU stay, or mortality during the 28-day study period, were recorded. Healthy control samples were obtained from healthy donors. This protocol was approved by the Clinical Research Ethics Committee of Chongqing Medical University (Institutional Review Board of Children’s Hospital of Chongqing Medical University, File No: [2019] Ethical Review [Clinical Research] No. 23), and informed consent was obtained from all participants according to the Declaration of Helsinki.

Animal Model

Six- to eight-week-old male wild-type (WT) C57BL/6 mice (18–22g) were purchased from Beijing HFK Bioscience Co., Ltd, and heterozygous PK2 deficient mice (PK2±) C57BL/6 mice were purchased from Cyagen Biosciences Inc. All mice were raised at SPF laboratory of Chongqing Medical University. The animal experiments were done in accordance with the Chongqing Medical University Institutional Animal Care and Use Committee’s guidelines. A polymicrobial sepsis model was induced by cecal ligation and puncture (CLP) as described in our previous studies (28–30). Briefly, the mice were anesthetized with 1.5% pentobarbital sodium (75 mg/kg body weight) intraperitoneally, and then about 1 cm incision was made in the midline abdomen after skin disinfection. The cecum was exposed, ligated at the end 2/3, and punctured with a 26-gauge needle (nonsevere CLP) or with a 21-gauge needle (severe CLP). The cecum was then placed back in the peritoneal cavity, and the incision was closed with surgical staples. Sham-operated (control) animals underwent identical laparotomy operation; the cecum was exposed but not ligated or punctured. One milliliter of saline was subcutaneously administrated for resuscitation. Buprenorphine (0.05 mg/kg body weight) was injected intraperitoneally every 6 hours after surgery for postoperative pain relief until 48 hours after surgery. A humane endpoint was used for the lethal CLP model.

In Vivo Administration of Recombinant Proteins

For in vivo prokineticin2 treatment, each mouse was injected intraperitoneally with 100 ng of murine rPK2 (PeproTech, Rocky Hill, NJ) or phosphate-buffered saline (PBS) after surgery and then 50 ng per mice intraperitoneally daily as a maintenance dose.

Statistical Analysis

The data are presented as mean ± sd. Comparisons between groups were tested by Mann-Whitney U test. Log-rank tests were performed for survival studies. All analyses were done with GraphPad Prism Version 9.0.0 (GraphPad Software, San Diego, CA). p values less than 0.05 were considered statistically significant.


Prokineticin2 Concentration Is Significantly Decreased in Patients With Severe Sepsis

As a start point in our analysis of the relationship between prokineticin2 and the progression of sepsis, blood samples from both adult and pediatric patients afflicted with sepsis and septic shock were assessed alongside patient controls and healthy control individuals (characteristics of patients with sepsis and controls are shown in Supplemental Table 1 [] and Supplemental Table 2 []). Patients with severe pneumonia were used as a control for nonseptic infected patients. As expected, it was found that levels of prokineticin2 in both adult (n = 47) and pediatric (n = 31) patients with sepsis were significantly reduced with respect to healthy control subjects and patient control subjects. In addition, patients with septic shock had lower prokineticin2 than those with sepsis (Fig. 1, A and B). Although the healthy control and patient groups were not well matched for age, we found no correlation between age and prokineticin2 serum concentration (data not shown) and do not think this difference explains the patterns seen. The above results suggest a potential role for prokineticin2 as a biomarker of sepsis and septic shock.

Figure 1.:

Serum prokineticin2 (PK2) levels were significantly decreased in patients with severe sepsis. A, PK2 concentrations were measured by enzyme-linked immunosorbent assay (ELISA) in serum samples collected from 47 adult patients with sepsis and septic shock, from 19 patients control with severe pneumonia, and from 30 healthy control subjects. B, PK2 concentration was measured by ELISA in serum samples collected from 31 pediatric patients with sepsis and septic shock, from 10 patients control with severe pneumonia, and from 20 healthy control subjects. C, The concentration of PK2 in serum were detected in adult patients who died of sepsis or septic shock and those who survived. Horizontal bars represent median values, and dots represent individual participants. *p < 0.05, **p < 0.01 compared between groups (denoted by horizontal bracket; Mann-Whitney U test).

To further evaluate the role of prokineticin2 levels in predicting mortality in adult patients with sepsis and septic shock, we analyzed the relationship between prokineticin2 levels and mortality and found that patients with lower prokineticin2 levels had higher mortality. (Fig. 1C). This observation indicates that the concentration of prokineticin2 is inversely proportional to the severity of the disease. Overall, these data support that the notion of prokineticin2 in peripheral blood can be applied as a significant biomarker for progression and severity of the disease and predicting death in patients with sepsis and septic shock.

Prokineticin2 Potentiation of Septic Mice Survival

To show a precise variation in patterns of prokineticin2 expression during the progression of sepsis, a CLP-induced sepsis mouse model was employed in which the levels of prokineticin2 were observed to increase mildly during onset of the disease and gradually diminished throughout the subsequent progression of sepsis (Supplemental Fig. 1, A and B,; legend, In view of the above, it was deemed essential to ascertain a more precise role of prokineticin2 in the onset and development of sepsis. Since it is difficult to obtain homozygous prokineticin2-deficient mice for their dysgeneses, we performed the survival rate experiment with prokineticin2 heterozygous (PK2±) mice and WT mice. The results showed that the survival rate of sepsis PK2± mice (0%) was significantly lower than that of WT mice (37.5%) (Fig. 2A). Meanwhile, PK2± mice lost weight faster than WT mice (Fig. 2B). Furthermore, the survival of septic mice after rPK2 administration was significantly improved in both WT mice and PK2± mice (Fig. 2, C and D). Moreover, significantly reduced bacteria loads were observed in samples of peritoneal lavage fluid (PLF), blood, and spleen tissues from within rPK2-treated septic WT mice and PK2± mice compared with PBS control septic animals (Supplemental Fig. 2, A and B,; legend,

F2Figure 2.:

Administration of recombinant prokineticin2 (rPK2) protected mice from lethal experimental sepsis. A and B, Lethal sepsis model was induced by cecal ligation and puncture (CLP) with wild-type (WT) mice and heterozygous PK2 deficient mice (PK2±) mice; the survival and weight were then observed for 2 wk. Comparison of survival curves was by Log-rank (Mantel-Cox) test. C, C57BL/6 mice (18–22 g) underwent CLP to induce a lethal sepsis model (n = 8–12), followed by intraperitoneal injection of different doses of rPK2, with half the initial dose daily as a maintenance dose, and observed the survival for up to 2 wk. Comparison of survival curves was by Log-rank (Mantel-Cox) test. D, PK2± mice (n = 5–8 per group) were subjected to lethal CLP, and then phosphate-buffered saline or rPK2 (100 ng/mouse) was administrated for each group. The survival rate was observed for 2 wk. Comparison of survival curves was by Log-rank (Mantel-Cox) test. BSA = bovine serum albumin.

In addition, organ damage in sepsis progression observed through histologic examinations of hematoxylin eosin-stained tissues from PBS controls compared with rPK2-treated animals was performed (Supplemental Fig. 3,; legend, Within PBS control animals, lung tissue injury was more prevalent as determined by severe hemorrhaging within, leukocyte infiltration of, exudation from, and destruction of alveolar wall tissue (Supplemental Fig. 3,; legend, Furthermore, hepatic tissue damage within these animals was exacerbated in the formation of irregular hepatocyte arrays and severe vesicular degeneration accompanied by a significant infiltration of inflammatory cells compared with corresponding tissue from the rPK2-treated animals (Supplemental Fig. 3,; legend, In spite of these, no morphologic changes were observed within spleen or renal tissues of the control group, although functional changes may exist. At the molecular level, biochemical markers indicative of tissue damage were partially reduced within rPK2-treated group (Supplemental Fig. 2C,; legend,, and overall, these observations confirm a protective function of prokineticin2 during sepsis.

The Protective Role of Prokineticin2 Is Macrophage Dependent

Increasingly, evidence supports the notion that macrophage involvement in sepsis could potentially alter the prognosis of the disease (28–31), although it is uncertain whether this bares similarities to their involvement in cancer and other inflammatory conditions (36,49,50). It also remains unclear whether rPK2 contributes to neutrophil and macrophage recruitment and activation during sepsis. In order to verify these processes, the WBC count in PLFs was obtained from improved Neubauer hemocytometry, and leucocyte morphology was observed by Wright’s staining in samples obtained from prokineticin2-treated and PBS control mice. No significant differences were observed in either WBC abundance or leucocyte morphology between the two groups (Supplemental Fig. 4, A and B,; legend, Thus, flow cytometry experiments were performed to ascertain whether any observable differences in the abundance of infiltrating leukocytes after CLP within PLF between the rPK2-treated and control groups could be observed. Once again, little or no discernable difference in either total cell count or proportions of different cell types was observed between the two groups (Supplemental Fig. 4C,; legend, These findings contradict previous observations which suggested prokineticin2 plays a role in neutrophil and macrophage chemotaxis (46,51) despite the fact that phagocytic and bactericidal function of macrophages is significantly elevated in rPK2-treated animals (Supplemental Fig. 4D, and Supplemental Fig. 5, [legend,]).

We further assessed the importance of macrophages in the survival of rPK2-treated septic mice after severe CLP by depletion of macrophage numbers in the presence of clodronate-encapsulated liposomes. In this, rPK2-treated septic mice survival was dramatically reduced when compared with PBS-encapsulated liposome-treated control mice (Fig. 3A). It is also noteworthy that bacterial clearances within the peritoneal cavity and in the blood were adversely affected owing to macrophage depletion within control animals (Fig. 3B). To determine whether prokineticin2 itself has a direct antimicrobial effect, the growth curves of the bacteria after the addition of rPK2 were also observed. However, no differences were observed in bacterial growth curves with different rPK2 concentrations (Supplemental Fig. 6,; legend,, indicating that prokineticin2 itself has no direct antibacterial effect. These findings clearly support the essential role ascribed to macrophages in prokineticin2-mediated protection against sepsis.

F3Figure 3.:

Prokineticin2 regulates macrophage function during sepsis. A and B, Forty-eight hours before the survival experiment and the bacterial load experiment, clodronate-encapsulated liposomes and phosphate-buffered saline (PBS)-encapsulated liposomes were intraperitoneally administered to exhaust the macrophages. C57BL/6 mice (18–22g, n = 5–8 per group) were subjected to lethal cecal ligation and puncture (CLP) surgery with a 26-gauge needle, followed by intraperitoneal injection of recombinant prokineticin2 (rPK2) (100 ng) or PBS, with half the initial dose daily as a maintenance dose, and observed the survival for up to 2 wk. Three independent experiments were performed. **p < 0.01, comparison of survival curves by Log-rank (Mantel-Cox) test. C57BL/6 mice (n = 5–8 per group) were subjected to sublethal CLP with a 26-gauge needle and then intraperitoneally injected with PBS or rPK2 (100 ng/mouse). Twenty-four/48 hours later, the number of bacterial colonies from blood, spleen, and peritoneal lavage fluid was counted after 24-hr culture with blood agar. *p < 0.05, **p < 0.01 when compared with control group (Mann-Whitney U test). CFU = colony-forming unit.

Prokineticin2 Regulates Macrophage Function Through Prokineticin2-PKR1-STAT3 Pathway

Prokineticin2 treatment appears to be involved in sepsis regression and alleviates tissue damage presumably in a macrophage-mediated prokineticin2-dependent fashion. In addition, it has previously been suggested that two structural isoforms of PKRs (PKR1 and PKR2) mediate prokineticin2 signaling. Prokineticin2 can bind to and activate both receptors resulting in different biological functions (52). It was, therefore, deemed essential to investigate further the prokineticin2 signaling pathway within macrophages, and three additional experiments were performed.

First, prokineticin2 activity in enhancing the phagocytic and bactericidal function of macrophages was indirectly assessed by monitoring the levels of macrophage receptor with collagenous structure (MARCO), a scavenger receptor of macrophages involved in phagocytosis, and inducible nitric oxide synthase (iNOS), an enzyme involved in bactericidal activity within rPK2-treated and untreated control macrophages. Little or no significant difference in the expressions of either MARCO or iNOS could be discerned between rPK2-treated and PBS control macrophages (Supplemental Fig. 7, A and B,; legend, In addition, rPK2 treatment of macrophages did not significantly alter secretion of common inflammatory cytokines, including interleukin (IL)–6, tumor necrosis factor-α, IL-10, and IL-17A (Supplemental Fig. 7C,; legend, In addition, rPK2 treatment of macrophages did not significantly alter secretion of common inflammatory cytokines, including interleukin (IL)–6, tumor necrosis factor-α, IL-10, and IL-17A (Supplemental Fig. 6C,; legend,

Second, quantitative polymerase chain reaction (qPCR) was employed to directly establish levels of expression from PKR1and PKR2 genes in macrophages stimulated with heat-killed Pseudomonas aeruginosa (multiplicity of infection = 100). It was found that PKR1 expression is slightly higher than PKR2 (Fig. 4A). To further clarify the role of prokineticin2 binding with different PKRs in regulating macrophages, we conducted phagocytosis and bactericidal experiments after short interfering RNA (siRNA) knockdown of the PKR isoforms. The knockdown of the targets was confirmed by qPCR and WB (Fig. 4B). The results showed that after interfering with PKR1, phagocytosis activity of macrophages was significantly reduced, although bactericidal action was largely unaltered (Fig. 4C). Neither phagocytic nor bactericidal functions were significantly changed after knockdown of PKR2 (Supplemental Fig. 7D,; legend, These findings suggest that prokineticin2 regulates the bacterial clearance function of macrophages in a prokineticin2-PKR1–dependent manner.

F4Figure 4.:

Prokineticin2 regulates macrophage function through prokineticin2-PKR1 pathway. A, The messenger RNA (mRNA) expression of prokineticin receptor 1 (PKR1) and prokineticin receptor 2 (PKR2) was determined by reverse transcriptase-polymerase chain reaction (PCR) (2–ΔΔCt). Data are expressed as mean values ± sd and were analyzed using the nonparametric Mann-Whitney U test. *p < 0.05, compared between two groups. B, The knockdown of the target PKRs were confirmed by quantitative PCR and WB. ***p < 0.001 when compared with control group (Mann-Whitney U test). C, The appropriate number of peritoneal macrophage (PMφ) were cultured in serum-free Dulbecco’s modified eagle medium (DMEM) and transfected with the corresponding short interfering RNA (siRNA) reagents, and the transfection efficiency was detected. Then transfected cells were treated with phosphate-buffered saline (PBS) or recombinant prokineticin2 (rPK2) (10 ng/mL) for 12 hr and challenged with Pseudomonas aeruginosa for 30 min and then half of the cells plated to blood agar after a 10-fold series of dilution for phagocytosis. The other half of the cells were incubated another 90 min and then plated to blood agar after a 10-fold series of dilution for killing. *p < 0.05, **p < 0.01 when compared with control group (Mann-Whitney U test). D, rPK2 (10 ng/mL) and PBS-treated PMφ were collected and extracted protein for Western blot test. 2–ΔΔCt is a method for quantitative analysis of fluorescence data by quantitative reverse transcription-PCR. CFU = colony-forming unit, p-STAT3 = phosphorylated STAT3.

Further studies of the signaling pathway revealed that rPK2 promoted STAT3 phosphorylation by 15 and 30 minutes in rPK2-treated macrophages compared with control, whereas other signaling pathways remained unaltered (Fig. 4D). Several studies have found that the STAT3 pathway is involved in the regulation of macrophage phenotype and function in a variety of diseases. Thus, phagocytosis experiments were performed after blocking STAT3 with the specific inhibitors S3I-20 and showed that prokineticin2 did not effectively enhance the phagocytic function of macrophages after STAT3 inhibition (Supplemental Fig. 8,; legend, This finding suggests that prokineticin2 regulates the phagocytic function of macrophages in a prokineticin2-PKR1-STAT3–dependent manner.


In the current study, a previously unrecognized role of prokineticin2 in regulating the host immune response during sepsis has been elucidated. This study determined a central role of prokineticin2 in alleviating sepsis-induced death by regulation of both macrophage function and inflammation response, which presents a new strategy for sepsis immunotherapy. This present study is of significance for both the diagnosis and treatment of sepsis. In terms of diagnosis, the insufficiency of prokineticin2 is closely related to deterioration in patient wellbeing, suggesting that continuous detection of prokineticin2 may be contributory to the diagnosis of sepsis/septic shock and the progress of recovery. Another important value of prokineticin2 we found is its ability to predict death in patients with sepsis and septic shock. The uniqueness of prokineticin2 as a novel biomarker in sepsis diagnostics lays in the fact that it is down-regulated during sepsis just similar to a negative acute phase reaction protein, whereas concentrations of existing markers appear to be elevated.

As treatment of sepsis, we demonstrate that prokineticin2 plays a protective role thereby improving survival rates in septic mice through enhancement of macrophage-mediated bacterial clearance. Animal experiments showed that the protective effect of prokineticin2 in sepsis was enhanced with the increase of the dosage in a certain range. So, replenishment of rPK2 may be a novel strategy for the treatment of sepsis and septic shock in patients with low prokineticin2 levels. These activities, therefore, circumvent an otherwise dire clinical prognosis for patients, where insufficient levels of prokineticin2 are a major hazard in sepsis progression, suggesting the value of prokineticin2 as a potential new drug. However, considering the concentration variation pattern of prokineticin2 in septic mouse models and the apparent biphasic response, it is worth noting that the safety dose range of prokineticin2 needs to be precisely determined in preclinical research through pharmaceutical studies, because excessive doses may have adverse effects as suggested by animal experiments. The other thing worth mentioning is that the CLP model may not completely mimic normal practice human fecal peritonitis as antibiotics were not used in the experiment, so more research on clinical and animal trials is needed.

Despite the significant protective effect of prokineticin2 during sepsis, the reason why prokineticin2 levels decrease during sepsis remains unclear. Previously, neutrophils and other WBCs were deemed to be important sources of prokineticin2 (49,51). Moreover, sufferers of severe sepsis are also afflicted with immunosuppression, primarily as a consequence of a reduction in WBC numbers and immune cell paralysis, which must also surely result in significantly reduced levels of prokineticin2 expression. Moreover, a splice variant of prokineticin2, PK2L (a long form of prokineticin2, PK2β), which has a different in vivo distribution and function to prokineticin2, has recently been isolated (53). In addition, it remains unclear whether prokineticin2 levels physiologically change at 72 hours in neonates akin to the effects of other biomarkers; for example, procalcitonin which, thereby forced doctors to make additional adjustments when using it.

In this study, we found that prokineticin2 levels have potential value in predicting mortality in adult patients with sepsis and septic shock. However, this analysis was not performed in children because only two deaths in children with sepsis and septic shock were included in our data, which made statistical analysis difficult.

In the current study, we provided direct evidence that prokineticin2 enhances the phagocytic bactericidal function of macrophages. The regulation of prokineticin2 on macrophages provides us with a new understanding of the innate immune regulation of sepsis, which may help us to further reveal the pathogenic mechanisms of sepsis. In consideration of the fact that sepsis is a life-threatening, multiple organ dysfunctional condition as a consequence of impaired host response to infection and given that the receptor for prokineticin2 is widely expressed in other tissues (52), it is plausible that prokineticin2 also directly acts within other tissues to alleviate their dysfunction and thus improve survival. This notion also forms a basis for further study.

In a word, our study elaborated a previously unrecognized role of prokineticin2 in regulating the host immune response during sepsis, which provides new potential strategies for the diagnosis and immunotherapy of sepsis and septic shock.


We thank Lubei Rao (Department of Clinical Laboratory, Children’s Hospital of Chongqing Medical University) and Hongdong Li (Department of Neonatology, Children’s Hospital of Chongqing Medical University) for clinical samples collection.


1. Singer M, Deutschman CS, Seymour CW, et al.: The third international consensus definitions for sepsis and septic shock (Sepsis-3). JAMA 2016; 315:801–810

2. Fleischmann C, Scherag A, Adhikari NK, et al.; International Forum of Acute Care Trialists: Assessment of global incidence and mortality of hospital-treated sepsis. Current estimates and limitations. Am J Respir Crit Care Med 2016; 193:259–272

3. Global Sepsis Alliance: World Sepsis Day. 2019. Available at: Accessed September 16, 2021

4. Kahn JM, Davis BS, Yabes JG, et al.: Association between state-mandated protocolized sepsis care and in-hospital mortality among adults with sepsis. JAMA 2019; 322:240–250

5. Laterre PF, Berry SM, Blemings A, et al.; SEPSIS-ACT Investigators: Effect of selepressin vs placebo on ventilator- and vasopressor-free days in patients with septic shock: The SEPSIS-ACT randomized clinical trial. JAMA 2019; 322:1476–1485

6. Wong HR, Caldwell JT, Cvijanovich NZ, et al.: Prospective clinical testing and experimental validation of the pediatric sepsis biomarker risk model. Sci Transl Med 2019; 11:eaax9000

7. Hernández G, Ospina-Tascón GA, Damiani LP, et al.; The ANDROMEDA SHOCK Investigators and the Latin America Intensive Care Network (LIVEN): Effect of a resuscitation strategy targeting peripheral perfusion status vs serum lactate levels on 28-day mortality among patients with septic shock: The ANDROMEDA-SHOCK randomized clinical trial. JAMA 2019; 321:654–664

8. Levy MM, Rhodes A, Phillips GS, et al.: Surviving Sepsis Campaign: Association between performance metrics and outcomes in a 7.5-year study. Crit Care Med 2015; 43:3–12

9. Rhodes A, Phillips G, Beale R, et al.: The Surviving Sepsis Campaign bundles and outcome: Results from the international multicentre prevalence study on sepsis (the IMPreSS study). Intensive Care Med 2015; 41:1620–1628

10. Mullard A: Drug withdrawal sends critical care specialists back to basics. Lancet 2011; 378:1769

11. Reinhart K, Daniels R, Kissoon N, et al.: Recognizing sepsis as a global health priority – A WHO resolution. N Engl J Med 2017; 377:414–417

12. Faix JD: Biomarkers of sepsis. Crit Rev Clin Lab Sci 2013; 50:23–36

13. Chiesa C, Pellegrini G, Panero A, et al.: C-reactive protein, interleukin-6, and procalcitonin in the immediate postnatal period: Influence of illness severity, risk status, antenatal and perinatal complications, and infection. Clin Chem 2003; 49:60–68

14. Lapillonne A, Basson E, Monneret G, et al.: Lack of specificity of procalcitonin for sepsis diagnosis in premature infants. Lancet 1998; 351:1211–1212

15. Bosmann M, Ward PA: The inflammatory response in sepsis. Trends Immunol 2013; 34:129–136

16. Hotchkiss RS, Monneret G, Payen D: Immunosuppression in sepsis: A novel understanding of the disorder and a new therapeutic approach. Lancet Infect Dis 2013; 13:260–268

17. Alves-Filho JC, Spiller F, Cunha FQ: Neutrophil paralysis in sepsis. Shock 2010; 34(Suppl 1):15–21

18. Sfeir T, Saha DC, Astiz M, et al.: Role of interleukin-10 in monocyte hyporesponsiveness associated with septic shock. Crit Care Med 2001; 29:129–133

19. Hotchkiss RS, Tinsley KW, Swanson PE, et al.: Depletion of dendritic cells, but not macrophages, in patients with sepsis. J Immunol 2002; 168:2493–2500

20. Giamarellos-Bourboulis EJ, Tsaganos T, Spyridaki E, et al.: Early changes of CD4-positive lymphocytes and NK cells in patients with severe Gram-negative sepsis. Crit Care 2006; 10:R166

21. Levi M, van der Poll T: Coagulation and sepsis. Thromb Res 2017; 149:38–44

22. Levi M, ten Cate H, van der Poll T, et al.: Pathogenesis of disseminated intravascular coagulation in sepsis. JAMA 1993; 270:975–979

23. Murao S, Yamakawa K: A systematic summary of systematic reviews on anticoagulant therapy in sepsis. J Clin Med 2019; 8:E1869

24. Friedrich O, Reid MB, Van den Berghe G, et al.: The sick and the weak: Neuropathies/myopathies in the critically ill. Physiol Rev 2015; 95:1025–1109

25. Stubbs DJ, Yamamoto AK, Menon DK: Imaging in sepsis-associated encephalopathy–Insights and opportunities. Nat Rev Neurol 2013; 9:551–561

26. Delano MJ, Ward PA: The immune system’s role in sepsis progression, resolution, and long-term outcome. Immunol Rev 2016; 274:330–353

27. Delano MJ, Ward PA: Sepsis-induced immune dysfunction: Can immune therapies reduce mortality? J Clin Invest 2016; 126:23–31

28. Song Z, Zhang X, Zhang L, et al.: Progranulin plays a central role in host defense during sepsis by promoting macrophage recruitment. Am J Respir Crit Care Med 2016; 194:1219–1232

29. Song Z, Zhang J, Zhang X, et al.: Interleukin 4 deficiency reverses development of secondary Pseudomonas aeruginosa pneumonia during sepsis-associated immunosuppression. J Infect Dis 2015; 211:1616–1627

30. Tao X, Song Z, Wang C, et al.: Interleukin 36α attenuates sepsis by enhancing antibacterial functions of macrophages. J Infect Dis 2017; 215:321–332

31. Lin X, Luo H, Yan X, et al.: Interleukin-34 ameliorates survival and bacterial clearance in polymicrobial sepsis. Crit Care Med 2018; 46:e584–e590

32. Gao X, Liu Y, Xu F, et al.: Assessment of apoptosis inhibitor of macrophage/CD5L as a biomarker to predict mortality in the critically ill with sepsis. Chest 2019; 156:696–705

33. Mollay C, Wechselberger C, Mignogna G, et al.: Bv8, a small protein from frog skin and its homologue from snake venom induce hyperalgesia in rats. Eur J Pharmacol 1999; 374:189–196

34. Li M, Bullock CM, Knauer DJ, et al.: Identification of two prokineticin cDNAs: Recombinant proteins potently contract gastrointestinal smooth muscle. Mol Pharmacol 2001; 59:692–698

35. Lattanzi R, Maftei D, Petrella C, et al.: Involvement of the chemokine prokineticin-2 (PROK2) in Alzheimer’s disease: From animal models to the human pathology. Cells 2019; 8:E1430

36. Li Y, Wang J, Yu L, et al.: Effects of prokineticin 2 on testicular inflammation in rats. Am J Reprod Immunol 2018; 79:e12843

37. Monnier J, Piquet-Pellorce C, Feige JJ, et al.: Prokineticin 2/Bv8 is expressed in Kupffer cells in liver and is down regulated in human hepatocellular carcinoma. World J Gastroenterol 2008; 14:1182–1191

38. Shojaei F, Singh M, Thompson JD, et al.: Role of Bv8 in neutrophil-dependent angiogenesis in a transgenic model of cancer progression. Proc Natl Acad Sci U S A 2008; 105:2640–2645

39. Soga T, Matsumoto Si, Oda T, et al.: Molecular cloning and characterization of prokineticin receptors. Biochim Biophys Acta 2002; 1579:173–179

40. Negri L, Ferrara N: The prokineticins: Neuromodulators and mediators of inflammation and myeloid cell-dependent angiogenesis. Physiol Rev 2018; 98:1055–1082

41. Lichtenauer M, Jung C: TBX20 and the PROK2-PROKR1 pathway-new kid on the block in angiogenesis research. Ann Transl Med 2018; 6:S8

42. Zhou QY, Cheng MY: Prokineticin 2 and circadian clock output. FEBS J 2005; 272:5703–5709

43. Traboulsi W, Brouillet S, Sergent F, et al.: Prokineticins in central and peripheral control of human reproduction. Horm Mol Biol Clin Investig 2015; 24:73–81

44. Xiao L, Zhang C, Li X, et al.: Signaling role of prokineticin 2 on the estrous cycle of female mice. PLoS One 2014; 9:e90860

45. Negri L, Maftei D: Targeting the prokineticin system to control chronic pain and inflammation. Curr Med Chem 2018; 25:3883–3894

46. Neal M, Luo J, Harischandra DS, et al.: Prokineticin-2 promotes chemotaxis and alternative A2 reactivity of astrocytes. Glia 2018; 66:2137–2157

47. Musher DM, Thorner AR: Community-acquired pneumonia. N Engl J Med 2014; 371:1619–1628

48. Olson G, Davis AM: Diagnosis and treatment of adults with community-acquired pneumonia. JAMA 2020; 323:885–886

49. Sasaki S, Baba T, Muranaka H, et al.: Involvement of prokineticin 2-expressing neutrophil infiltration in 5-fluorouracil-induced aggravation of breast cancer metastasis to lung. Mol Cancer Ther 2018; 17:1515–1525

50. Martucci C, Franchi S, Giannini E, et al.: Bv8, the amphibian homologue of the mammalian prokineticins, induces a proinflammatory phenotype of mouse macrophages. Br J Pharmacol 2006; 147:225–234

51. Giannini E, Lattanzi R, Nicotra A, et al.: The chemokine Bv8/prokineticin 2 is up-regulated in inflammatory granulocytes and modulates inflammatory pain. Proc Natl Acad Sci U S A 2009; 106:14646–14651

52. Zhao Y, Wu J, Wang X, et al.: Prokineticins and their G protein-coupled receptors in health and disease. Prog Mol Biol Transl Sci 2019; 161:149–179

53. Lattanzi R, Maftei D, Negri L, et al.: PK2β ligand, a splice variant of prokineticin 2, is able to modulate and drive signaling through PKR1 receptor. Neuropeptides 2018; 71:32–42